|   From the Trenches

Leadership At All Levels In Biotech

Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science, and have endurance for the many years it takes to develop a new medicine. In addition, professionals who thrive in biotech have the know-how, confidence and guts to tackle business goals that are covered in uncertainty and complexity. These are ‘hard core’ leadership traits, and they are highly valued in biotech companies at all levels of job responsibilities.

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   LifeSciVC

Venture Volatility: 2018’s Banner Year Closed Cautiously

By Bruce Booth, DPhil, Partner

2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era.

Read more.


  |   LifeSciVC

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference

By Bruce Booth, DPhil, Partner

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry.

Read more.


  |   News

Atlas Venture’s 2018 Year in Review

2018 was an active and exciting year in the Atlas portfolio. Six of our portfolio companies went public, the drug developed by Arteaus was approved, we announced our first Opportunity Fund, and so much more. Check out our newsletter for the highlights.

Read more.


  |   LifeSciVC

Biotech IPO Market: Closing The Books On 2018’s Crazy Year

By Bruce Booth, DPhil, Partner

2018 was an incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third of the year was challenging – indices plummeting over 25% in four months.

Read more.